We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $118.00 as of January 26th. BNTX’s trailing and forward P/E were 166.87 and 7.04 respectively according to Yahoo Finance.
[caption id="attachment_575379" align="aligncenter" width="750"]BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. BNTX is entering 2026 as a transitional...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.